Veridien Third Quarter Revenues Increase by 69% over Same Period Last Year.

ST. PETERSBURG, Fla. -- Veridien Corporation (OTCBB:VRDE) announces revenue of $685,985 for the third quarter of 2004, up 69% over sales of $406,192 during the third quarter of 2003.

Third quarter General, Selling and Administrative expenses decreased by 40% to $208,715 as compared to third quarter 2003. As a percentage of sales these expenses represent only 30%, down from the level of 85% during third quarter last year.

Net Income year to date is $321,743, a net improvement of $668,526 over the loss of $346,783 at the same point during the last fiscal year.

Veridien continues to build upon its existing relationships and build new ones with strategic partners in both the distribution and manufacturing arenas.

Shelley Fenton, CEO and President, said, "For the first time in reported history, Veridien has emerged from a third quarter with a profit on the bottom line for the 9 month year-to-date figures, as well as being operationally profitable. We are pleased with the direction and growth in our profitability and relationships forged to generate increased sales."

About Veridien:

Veridien Corporation is a Health Care and Anti-Infectives Company focusing on Infection Control and other Healthy Lifestyle products. Veridien has developed patented and unique products including surface disinfectants, antiseptic hand cleansers, instrument presoak, and sun protectant products. The flagship product, Viraguard(R) Hospital Disinfectant/Cleaner and Instrument Presoak is a skin-friendly, patented, U.S. EPA and Health Canada registered, surface disinfectant. Viraguard(R) Antiseptic Hand Gel, Viraguard(R) Antiseptic Hand Spray and Viraguard(R) Antiseptic Hand Wipes are U.S. - FDA and Health Canada drug listed products utilizing Veridien's patented Virahol(R) formulation.

About Veridien's investment in future technology:

Veridien is developing new patented products in concert with Mycosol, Inc., a company in which Veridien has invested and has the right to acquire majority ownership interest. Mycosol is a development-stage chemical and pharmaceutical company based in the Research Triangle Park area of North Carolina. The Company is developing a proprietary, low cost platform technology with the objective being to safely and effectively treat and prevent microbial-induced and microbial-exacerbated problems. Mycosol's proprietary multi-active compound has demonstrated potent anti-mold, anti-fungal, anti-bacterial, anti-inflammatory, and anti-allergic properties. Based on this "core technology" platform, a library of over 1,500 known analogs and 5 patents pending, Mycosol believes that a broad portfolio of products can be developed for many medical, industrial, veterinary and agricultural applications.

Look for Veridien at http://veridien.com

Look for Mycosol at http://www.mycosol.com

Special Note: Forward-looking statements in this press release (identifiable by words such as "believes") are made pursuant to the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, market acceptance of, and demand for, the Company's products, manufacturing, development and distributor issues, product pricing, competition, funding availability, technological changes and other risks not identified herein. The Company disclaims any intent or obligation to update any forward-looking statements.

"Healthy Living is an Adventure - Let Veridien Guide You"